Philips Expands 3D Heart Imaging with VeriSight Pro in Europe, Enhancing Real-Time Imaging Without General Anesthesia.

Philips introduces VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe, enhancing real-time heart imaging without general anesthesia. The catheter provides high-resolution 2D and 3D visualization, aiding transcatheter valve repair and left atrial appendage closure procedures. VeriSight Pro integrates with Philips' EPIQ ultrasound systems and Azurion image-guided therapy platform, supporting complex procedures like mitral valve repair and atrial septal defect closure.

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) has announced the launch of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe, following its successful implementation in the United States. This innovative device features a miniaturized ultrasound probe, approximately 3 millimeters in diameter, embedded at the tip of a thin, steerable catheter. The probe provides real-time 2D and 3D imaging directly inside the heart, enabling high-resolution visualization for various structural heart procedures without the need for general anesthesia [1].

The VeriSight Pro catheter is designed to support procedures such as transcatheter valve repair and left atrial appendage closure, offering high-resolution 2D and 3D visualization directly within the heart chambers. This capability allows for confident clinical decision-making and precise device placement, all from a single access point [1].

The integration of VeriSight Pro with Philips' existing EPIQ ultrasound systems and Azurion image-guided therapy platform creates a comprehensive ecosystem for structural heart care. The catheter's unique features, including xPlane and iRotate technologies, allow physicians to visualize two imaging planes simultaneously and digitally adjust views without physically repositioning the catheter tip [1].

The launch of VeriSight Pro in Europe addresses the growing challenge of structural heart disease, with increasing volumes of transcatheter valve repair and closure procedures. Traditional methods, such as transesophageal echocardiography (TEE), often require general anesthesia, additional staff, and extended room time. In contrast, 3D ICE imaging provides detailed visualization from within the heart through a catheter introduced via the femoral vein, reducing the need for general anesthesia and recovery time in the Post-Anesthesia Care Unit (PACU), which can shorten hospital stays and lower costs [1].

The European launch of VeriSight Pro 3D ICE catheter represents a significant advancement in intracardiac imaging technology. This miniaturized ultrasound probe delivers real-time 2D and 3D visualization from inside the heart chambers, enabling physicians to perform complex structural heart procedures with enhanced precision. The elimination of general anesthesia requirements typically associated with TEE translates to reduced procedural complexity, shorter hospital stays, and lower overall costs for healthcare systems [2].

Philips will highlight VeriSight Pro and its role in structural heart interventions at EuroPCR 2025 in Paris, featuring physician-led symposiums, hands-on training, and VR-based demonstrations. The launch will expand Philips' cardiology portfolio with innovative 3D imaging technology, reducing procedure complexity and improving patient experience [2].

References:
[1] https://quantisnow.com/insight/philips-launches-realtime-3d-intracardiac-imaging-in-europe-expanding-access-to-minimally-invasive-heart-6046621
[2] https://www.stocktitan.net/news/PHG/philips-launches-real-time-3d-intracardiac-imaging-in-europe-jjhc24n5lvuy.html